244 results on '"Glaser, Keith B."'
Search Results
2. Supplementary Figure 1 from The Multitargeted Receptor Tyrosine Kinase Inhibitor Linifanib (ABT-869) Induces Apoptosis through an Akt and Glycogen Synthase Kinase 3β–Dependent Pathway
3. Corrigendum to “Future directions for the discovery of natural product-derived immunomodulating drugs: An IUPHAR positional review” [Pharmacol. Res. 177 (2022) 106076]
4. The 2021 Marine Pharmacology and Pharmaceuticals Pipeline
5. Future directions for the discovery of natural product-derived immunomodulating drugs
6. Bcl-XL represents a druggable molecular vulnerability during aurora B inhibitor-mediated polyploidization
7. 1-Benzyl-3-cetyl-2-methylimidazolium iodide (NH125) Induces Phosphorylation of Eukaryotic Elongation Factor-2 (eEF2): A CAUTIONARY NOTE ON THE ANTICANCER MECHANISM OF AN eEF2 KINASE INHIBITOR
8. The odyssey of marine pharmaceuticals: a current pipeline perspective
9. Inhibition of Phospholipase A2 Activation in P388D1 Macrophage-Like Cells
10. Macrophage Phospholipase A2 Activity and Eicosanoid Production: Studies with Phospholipase A2 Inhibitors in P388D1 Cells
11. Identification of VEGF Signaling Inhibition-Induced Glomerular Injury in Rats through Site-Specific Urinary Biomarkers
12. Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML
13. ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft
14. In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor
15. G1P3, an IFN-induced survival factor, antagonizes TRAIL-induced apoptosis in human myeloma cells
16. ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia
17. Cyanobacterial Microcystis aeruginosa Lipopolysaccharide Elicits Release of Superoxide Anion, Thromboxane B2, Cytokines, Chemokines, and Matrix Metalloproteinase-9 by Rat Microglia
18. The Marine Pharmacology and Pharmaceuticals Pipeline in 2020
19. A renaissance in marine pharmacology: From preclinical curiosity to clinical reality
20. G1P3, an IFN-induced survival factor, antagonizes TRAIL-induced apoptosis in human myeloma cells
21. HDAC inhibitors: Clinical update and mechanism-based potential
22. Expression and functional characterization of recombinant human HDAC1 and HDAC3
23. Fluorescence assay of SIRT protein deacetylases using an acetylated peptide substrate and a secondary trypsin reaction
24. Phospholipase A2 enzymes: regulation and inhibition
25. Role of Class I and Class II histone deacetylases in carcinoma cells using siRNA
26. Regulation of Phospholipase A2 Enzymes: Selective Inhibitors and their Pharmacological Potential
27. The Marine Pharmacology and Pharmaceuticals Pipeline in 2018
28. Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD+ biosynthesis pathway and NAMPT mutation
29. Macrophage Phospholipase A2 Activity and Eicosanoid Production: Studies with Phospholipase A2 Inhibitors in P388D1 Cells
30. The Marine Pharmacology and Pharmaceuticals Pipeline in 2017
31. Enhancement of the surface expression of tumor necrosis factor α (TNFα) but not the p55 TNFα receptor in the THP-1 monocytic cell line by matrix metalloprotease inhibitors
32. The Marine Pharmacology and Pharmaceuticals Pipeline in 2016
33. The Marine Pharmacology and Pharmaceuticals Pipeline in 2015
34. Exploration of diverse hinge-binding scaffolds for selective Aurora kinase inhibitors
35. Pyrazole diaminopyrimidines as dual inhibitors of KDR and Aurora B kinases
36. Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families
37. JAK2V617F Drives Mcl-1 Expression and Sensitizes Hematologic Cell Lines to Dual Inhibition of JAK2 and Bcl-xL
38. Discovery of potent and selective thienopyrimidine inhibitors of Aurora kinases
39. Marine Pharmacology and the Marine Pharmaceuticals Pipeline
40. Abstract 3450: ABT-348 in combination with inhibition of CDK4/6 highlights a strategy to target RB mutant cells while sparing RB wild-type cells.
41. Scaffold oriented synthesis. Part 2: Design, synthesis and biological evaluation of pyrimido-diazepines as receptor tyrosine kinase inhibitors
42. Identification of aminopyrazolopyridine ureas as potent VEGFR/PDGFR multitargeted kinase inhibitors
43. Preclinical Characterization of ABT-348, a Kinase Inhibitor Targeting the Aurora, Vascular Endothelial Growth Factor Receptor/Platelet-Derived Growth Factor Receptor, and Src Kinase Families
44. Abstract 1818: The Aurora B inhibitor ABT-348 is not susceptible to known resistance mechanisms of other Aurora B inhibitors
45. Marine-Derived Pharmaceuticals in Clinical Trials in 2022
46. Abstract C202: Discovery and initial characterization of the clinical compound ABT-348, a potent inhibitor of the VEGF, PDGF, and Aurora kinase families.
47. Abstract A239: Preclinical characterization of ABT-348, a kinase inhibitor targeting the Aurora, VEGFR/PDGFR, and SRC kinase families.
48. The Multitargeted Receptor Tyrosine Kinase Inhibitor Linifanib (ABT-869) Induces Apoptosis through an Akt and Glycogen Synthase Kinase 3β–Dependent Pathway
49. Abstract 12: JAK2V617F drives Mcl-1 expression and sensitizes acute myeloid leukemia cells to dual inhibition of JAK2 and Bcl-XL
50. ABT-869 Inhibits the Proliferation of Ewing Sarcoma Cells and Suppresses Platelet-Derived Growth Factor Receptor β and c-KIT Signaling Pathways
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.